These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2128745

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs.
    Grover GJ, Sleph PG, Dzwonczyk S.
    J Cardiovasc Pharmacol; 1990 Dec; 16(6):853-64. PubMed ID: 1704976
    [Abstract] [Full Text] [Related]

  • 3. Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat hearts.
    Sargent CA, Wilde MW, Dzwonczyk S, Tuttle JG, Murray HN, Atwal K, Grover GJ.
    Cardiovasc Res; 1996 Feb; 31(2):270-7. PubMed ID: 8730404
    [Abstract] [Full Text] [Related]

  • 4. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate.
    McCullough JR, Normandin DE, Conder ML, Sleph PG, Dzwonczyk S, Grover GJ.
    Circ Res; 1991 Oct; 69(4):949-58. PubMed ID: 1934346
    [Abstract] [Full Text] [Related]

  • 5. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
    Lee SH, Yang MK, Lim JH, Seo HW, Yi KY, Yoo SE, Lee BH, Won HS, Lee CS, Choi WS, Shin HS.
    Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
    [Abstract] [Full Text] [Related]

  • 6. Calcium-activated potassium channel triggers cardioprotection of ischemic preconditioning.
    Cao CM, Xia Q, Gao Q, Chen M, Wong TM.
    J Pharmacol Exp Ther; 2005 Feb; 312(2):644-50. PubMed ID: 15345753
    [Abstract] [Full Text] [Related]

  • 7. The KATP blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts.
    Grover GJ, Murray HN, Baird AJ, Dzwonczyk S.
    Eur J Pharmacol; 1995 Apr 24; 277(2-3):271-4. PubMed ID: 7493619
    [Abstract] [Full Text] [Related]

  • 8. Cardioprotective effects of stretch are mediated by activation of sarcolemmal, not mitochondrial, ATP-sensitive potassium channels.
    Mosca SM.
    Am J Physiol Heart Circ Physiol; 2007 Aug 24; 293(2):H1007-12. PubMed ID: 17400714
    [Abstract] [Full Text] [Related]

  • 9. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
    Grover GJ, D'Alonzo AJ, Garlid KD, Bajgar R, Lodge NJ, Sleph PG, Darbenzio RB, Hess TA, Smith MA, Paucek P, Atwal KS.
    J Pharmacol Exp Ther; 2001 Jun 24; 297(3):1184-92. PubMed ID: 11356945
    [Abstract] [Full Text] [Related]

  • 10. The cardioprotective effect of naringenin against ischemia-reperfusion injury through activation of ATP-sensitive potassium channel in rat.
    Meng LM, Ma HJ, Guo H, Kong QQ, Zhang Y.
    Can J Physiol Pharmacol; 2016 Sep 24; 94(9):973-8. PubMed ID: 27408985
    [Abstract] [Full Text] [Related]

  • 11. Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury--Evidence for a role of K ATP channels.
    Johansen D, Ytrehus K, Baxter GF.
    Basic Res Cardiol; 2006 Jan 24; 101(1):53-60. PubMed ID: 16328106
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning.
    Auchampach JA, Maruyama M, Cavero I, Gross GJ.
    Circulation; 1992 Jul 24; 86(1):311-9. PubMed ID: 1301066
    [Abstract] [Full Text] [Related]

  • 13. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
    Sargent CA, Smith MA, Dzwonczyk S, Sleph PG, Grover GJ.
    J Pharmacol Exp Ther; 1991 Oct 24; 259(1):97-103. PubMed ID: 1920138
    [Abstract] [Full Text] [Related]

  • 14. Monophosphoryl lipid A attenuates myocardial stunning in dogs: role of ATP-sensitive potassium channels.
    Elliott GT, Mei DA, Gross GJ.
    J Cardiovasc Pharmacol; 1998 Jul 24; 32(1):49-56. PubMed ID: 9676720
    [Abstract] [Full Text] [Related]

  • 15. The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts.
    Grover GJ, Dzwonczyk S, Sleph PG, Sargent CA.
    J Pharmacol Exp Ther; 1993 May 24; 265(2):559-64. PubMed ID: 8496806
    [Abstract] [Full Text] [Related]

  • 16. Effects of the blockade of cardiac sarcolemmal ATP-sensitive potassium channels on arrhythmias and coronary flow in ischemia-reperfusion model in isolated rat hearts.
    Gok S, Vural K, Sekuri C, Onur R, Tezcan A, Izanli A.
    Vascul Pharmacol; 2006 Apr 24; 44(4):197-205. PubMed ID: 16495160
    [Abstract] [Full Text] [Related]

  • 17. Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts.
    Jung YS, Moon CH, Cho TS, Yoo SE, Shin HS.
    Jpn J Pharmacol; 1998 Jan 24; 76(1):65-73. PubMed ID: 9517406
    [Abstract] [Full Text] [Related]

  • 18. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
    Grover GJ, McCullough JR, Henry DE, Conder ML, Sleph PG.
    J Pharmacol Exp Ther; 1989 Oct 24; 251(1):98-104. PubMed ID: 2507775
    [Abstract] [Full Text] [Related]

  • 19. Effect of the potassium channel opener EMD 56431 on globally ischemic rat hearts.
    Sargent CA, Dzwonczyk S, Grover GJ.
    Pharmacology; 1992 Oct 24; 45(5):260-8. PubMed ID: 1465473
    [Abstract] [Full Text] [Related]

  • 20. Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim.
    Gross GJ, Mei DA, Sleph PG, Grover GJ.
    J Pharmacol Exp Ther; 1997 Feb 24; 280(2):533-40. PubMed ID: 9023261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.